spacer
home > ebr > autumn 2009 > the end of the line for paper
PUBLICATIONS
European Biopharmaceutical Review

The End of the Line for Paper

 

The biopharmaceutical environment is highly regulated, and therefore necessitates effective document management processes. In addition to the strict regulatory environment, which encompasses pharmaceutical documentation, organisations operating in this sector must also find ways of processing an increasing volume of information. Additionally, sponsor organisations must comply with increasing regulatory demands, particularly with respect to electronic submissions for approval.

To manage data efficiently, many companies are implementing electronic document management systems (eDMS) to assist in the storage and organisation of electronic records. The document lifecycle is controlled so that periodic reviews, regulatory changes and design modifications to the installed manufacturing plant, lab equipment and clinical trials, as well as re-training and assessment of operators, can all be managed within one seamless system. These systems are used for managing both digital and printed documents (once scanned in), and are flexible enough to allow existing documentation to be incorporated into the system while enabling full compliance with current regulatory standards. This article will discuss the increasing need for effective document management strategies within the pharmaceutical industry, the regulatory issues affecting pharmaceutical document management and the growing use of eDMS, in particular for biotech companies wth limited resources, both to purchase software, validate it and maintain it.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Keith Williams founded Good Products in 2006. Keith has many years of biopharmaceutical consultancy experience, particularly in computer systems validation, and computerised systems training in manufacturing, clinical and laboratory environments. He has a BSc in Genetics and Microbiology and an MSc in Biochemical Engineering.

Patrick Hughes joined Good Products in 2007 and is Senior VP, Strategic Business Development. Previously, Patrick worked for the clinical technology organisation, ClinPhone plc, in various senior management roles including sales and marketing, product management and strategic business development. These roles focused on the commercial management and strategic direction of IVR, ePRO, EDC, patient recruitment and CTMS technologies.

spacer
Keith Williams
spacer
spacer
spacer
Patrick Hughes
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Surge of Indian biosimilars market forecast in 2019

16th April 2019: New data from CPhI shows that, despite ongoing reputational challenges, India’s biologics market is set for robust growth in 2019 driven by biosimilars production. The India specific findings from CPhI’s bio league tables predict strong ‘bio growth potential’ in India throughout 2019 in the build-up to the 13th edition of CPhI India 2019, which will take place at the India Expo Centre in Delhi NCR.
More info >>

White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement